Raiden3t
Payments companies reported to CMS as associated with Raiden3t. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Raiden3t, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Raiden3t
These are the largest totals companies reported as associated with Raiden3t. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Erin Murphy | Charlotte, NC | Vascular Surgery | $99.88 |
| Trisha Roy | Houston, TX | Cardiovascular Disease | $32.16 |
| Miguel Montero | Houston, TX | Vascular & Interventional Radiology | $32.16 |
| Eric Secemsky | Boston, MA | Interventional Cardiology | $32.16 |
| Erin Murphy | Louisville, KY | Internal Medicine | $29.25 |
| David Lew | Leesburg, FL | Cardiovascular Disease | $19.76 |
| Michael Deluca | El Paso, TX | Interventional Cardiology | $15.02 |
| Mohammad Raja | El Paso, TX | Interventional Cardiology | $15.02 |
| Waseem Shami | El Paso, TX | Cardiovascular Disease | $15.02 |
Prescribed Raiden3t?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.